Clinical trial

Apatinib Combine With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer

NCT03050411

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2016-05-01

PhasePHASE1

Study timeline

Study start (unknown)2016-05-01Date precision: month

Registry last updated2017-02-10

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Nonsmall Cell Lung Cancerunresolved

Interventions

Apatinib Mesylate TabletsDRUG

EGFR-TKIs (Erlotinib, Gefitinib and Osimertinib)DRUG

Sponsors & collaborators

Peking University Third Hospitallead sponsor

Mapped research locations

BeijingBeijing Municipality, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03050411 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.